Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide


Agreement enables Abbott to provide coagulation testing solutions to labs with Sekisui's new CP3000 system.


ABBOTT PARK, Ill., April 14, 2015 /PRNewswire/ -- Today, Abbott (NYSE: ABT) and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.

"Abbott is committed to providing testing solutions that healthcare providers rely on for actionable information in diagnosing and treating various medical conditions," said Jaime Contreras, senior vice president, Commercial Operations, Diagnostics, Abbott. "Collaborating with Sekisui broadens our offerings within hematology, providing an important component needed to improve care for people around the world."

Coagulation testing helps clinicians in assessing people before many medical treatments and in monitoring those who take medications that can affect clotting. It is also useful in the diagnosis of blood-related disorders, such as hemophilia (when blood does not clot normally) and thrombosis (formation of a clot that blocks blood flow).

"Coagulation testing has been an important focus for Sekisui for over twenty years," said Robert Schruender, president and chief operating officer of Sekisui Diagnostics. "We are delighted that this relationship with Abbott will bring the benefits of our system, which is a leading product in Japan, to many customers around the world."

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Image credit: |
Medical team -- Image credit: Flamingo Images |
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin -
© 2024 MJH Life Sciences

All rights reserved.